BMRN

BioMarin Pharmaceutical Inc. Press Releases

$91.53
*  
3.35
3.8%
Get BMRN Alerts
*Delayed - data as of Dec. 26, 2014  -  Find a broker to begin trading BMRN now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
View:    BMRN Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing
Filtered By
Ordered By
BioMarin and Prosensa Announce Expiration of the Hart-Scott-Rodino Waiting Period for BioMarin''s Proposed Acquisition of Prosensa
12/24/2014 1:15:00 PM - GlobeNewswire


PROSENSA HOLDING N.V. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout
12/12/2014 12:40:00 PM - PR Newswire
▼-0.71 % Price Change since this news event. The Volume Ratio is 0.71.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


BioMarin's VIMIZIM(R) (elosulfase alfa) Approved in Brazil for Treatment of Morquio A Syndrome
12/10/2014 8:01:00 AM - GlobeNewswire


FDA Grants BioMarin Orphan Drug Designation for NAGLU Fusion Protein, BMN 250, for the Treatment of MPS IIIB (Sanfilippo Syndrome Type B)
12/10/2014 8:00:00 AM - GlobeNewswire


Cure Duchenne Offers Continued Support to BioMarin for Duchenne Research
12/10/2014 7:45:00 AM - Business Wire
▼-3.60 % Price Change since this news event. The Volume Ratio is 1.03.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


BioMarin to Highlight Breadth of Innovative Development Pipeline at Analyst and Investor Day on December 10th in New York
12/9/2014 8:00:00 AM - GlobeNewswire


BioMarin's VIMIZIM(R) (elosulfase alfa) Approved in Australia for Treatment of Morquio A Syndrome
12/7/2014 4:00:00 PM - GlobeNewswire


Prosensa Holding N.V. Acquisition By BioMarin Pharmaceutical Inc. May Not Be In The Best Interests of RNA Shareholders
12/3/2014 4:11:00 PM - PR Newswire


BioMarin to Host Analyst and Investor Day on December 10th in New York
12/3/2014 8:00:00 AM - GlobeNewswire


KaloBios Elects Robert A. Baffi, BioMarin Senior Executive, to Board of Directors
12/1/2014 8:05:00 AM - PR Newswire


BioMarin and Prosensa Holding N.V. Reach Agreement on Intended Public Offer for 100% of Prosensa's Outstanding Stock; Will Add Duchenne Muscular Dystrophy Products to Rare-Disease Portfolio
11/24/2014 6:00:00 AM - GlobeNewswire


BioMarin to Attend Upcoming Investor Conferences
11/19/2014 8:00:00 AM - GlobeNewswire


Jean-Jacques Bienaime, CEO of BioMarin, to Present at the Credit Suisse 2014 Healthcare Conference
11/4/2014 8:00:00 AM - GlobeNewswire


BioMarin Announces Third Quarter 2014 Financial Results
10/23/2014 4:01:00 PM - GlobeNewswire


BioMarin to Host Third Quarter 2014 Financial Results Conference Call and Webcast on Thursday, October 23 at 4:30pm ET
10/8/2014 8:00:00 AM - GlobeNewswire